AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17163102 — intervention group
Group type: EXPERIMENTAL
Intervention: EVAR (Endovascular Aneurysm Repair)
Number of subjects: 0
Study 17163102 — intervention group
Group type: EXPERIMENTAL
Intervention: EVAR
Number of subjects: 0
Study 17163102 — intervention group
Group type: COMPARATOR
Intervention: Open AAA repair
Number of subjects: 0
Study 15049856 — intervention group
Group type: EXPERIMENTAL
Intervention: 35% CO(2)
Number of subjects: 9
Study 15049856 — intervention group
Group type: COMPARATOR
Intervention: 5% CO(2)
Number of subjects: 9
Study 15049856 — intervention group
Group type: COMPARATOR
Intervention: 25% CO(2)
Number of subjects: 9
Study 15049856 — intervention group
Group type: COMPARATOR
Intervention: 50% CO(2)
Number of subjects: 9
Study 11722314 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behaviour Therapy (CBT), 10 sessions including cognitive methods, behavioural methods, problem-solving skills training, and behavioural counselling to significant others.
Number of subjects: 40
Study 11722314 — intervention group
Group type: COMPARATOR
Intervention: Routine medical treatment (Control group)
Number of subjects: 40
Study 9393272 — intervention group
Group type: EXPERIMENTAL
Intervention: Chest physiotherapy including breathing with pursed lips, huffing and coughing, and resistance training on inspiration and expiration with a mask (inspiration -5 cmH2O, expiration +10 cmH2O)
Number of subjects: 368
Study 9393272 — intervention group
Group type: COMPARATOR
Intervention: No treatment or information provided to the control group
Number of subjects: 368
Study 8192413 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrin glue
Number of subjects: 40
Study 8192413 — intervention group
Group type: COMPARATOR
Intervention: No fibrin glue (control)
Number of subjects: 40
Study 3259337 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (2.5 mg/kg)
Number of subjects: 62
Study 3259337 — intervention group
Group type: COMPARATOR
Intervention: Thiopental (4.0 mg/kg)
Number of subjects: 62
Study 28493407 — intervention group
Group type: EXPERIMENTAL
Intervention: First-person perspective video prior to simulation training
Number of subjects: 40
Study 28493407 — intervention group
Group type: COMPARATOR
Intervention: No video prior to simulation training
Number of subjects: 40
Study 28453780 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention
Number of subjects: 2806
Study 28453780 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 2806
Study 28453780 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2806
Study 26183034 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal-directed fluid therapy (GDFT) with the LiDCOrapid system
Number of subjects: 100
Study 26183034 — intervention group
Group type: COMPARATOR
Intervention: Routine fluid therapy (Control)
Number of subjects: 100
Study 23604798 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep Squat (DS)
Number of subjects: 17
Study 23604798 — intervention group
Group type: COMPARATOR
Intervention: Shallow Squat (SS)
Number of subjects: 17
Study 20006169 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermosetting gel containing 2.5% prilocaine and 2.5% lidocaine
Number of subjects: 35
Study 20006169 — intervention group
Group type: COMPARATOR
Intervention: Eugenol on a gauze strip
Number of subjects: 35
Study 20006169 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermosetting gel
Number of subjects: 35
Study 20006169 — intervention group
Group type: COMPARATOR
Intervention: Eugenol
Number of subjects: 35
Study 18472381 — intervention group
Group type: EXPERIMENTAL
Intervention: Rupatadine
Number of subjects: 0
Study 18472381 — intervention group
Group type: COMPARATOR
Intervention: Estazolam (internal standard)
Number of subjects: 0
Study 15895850 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 lift/min
Number of subjects: 10
Study 15895850 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 lifts/min
Number of subjects: 10
Study 15895850 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 lifts/min
Number of subjects: 10
Study 15895850 — intervention group
Group type: EXPERIMENTAL
Intervention: 70 x 35 x 15 cm
Number of subjects: 10
Study 15895850 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 x 50 x 15 cm
Number of subjects: 10
Study 14559418 — intervention group
Group type: EXPERIMENTAL
Intervention: Solid (filled) pictorials
Number of subjects: 0
Study 14559418 — intervention group
Group type: EXPERIMENTAL
Intervention: Pictorials 75% size of inner diameter of circle‐slash
Number of subjects: 0
Study 14559418 — intervention group
Group type: EXPERIMENTAL
Intervention: Pictorials with greater vertical DE (tall/thin)
Number of subjects: 0
Study 14559418 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagonal slashes
Number of subjects: 0
Study 14559418 — intervention group
Group type: EXPERIMENTAL
Intervention: Thickness of red circle‐slash comprising 25% of total area inside outer circle
Number of subjects: 0
Study 14559418 — intervention group
Group type: EXPERIMENTAL
Intervention: Thicker slash and smaller pictorial size
Number of subjects: 0
Study 9874712 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose thalidomide (200 mg, escalated to 1200 mg)
Number of subjects: 45
Study 9874712 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose thalidomide (200 mg, escalated to 1200 mg)
Number of subjects: 45
Study 8911877 — intervention group
Group type: EXPERIMENTAL
Intervention: Flosequinan (100 mg daily)
Number of subjects: 24
Study 8911877 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 1806811 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral DDAVP (150 to 600 micrograms/day)
Number of subjects: 13
Study 1806811 — intervention group
Group type: COMPARATOR
Intervention: Intranasal DDAVP
Number of subjects: 13
Study 6441815 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin synthetase promoter (263E) 500 mg three times daily
Number of subjects: 90
Study 6441815 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 400 mg at night
Number of subjects: 90
Study 6441815 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 31577678 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative antibiotics for 24 hours
Number of subjects: 552
Study 31577678 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative antibiotics for 72 hours
Number of subjects: 552
Study 27684541 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified dot-probe protocol (active)
Number of subjects: 113
Study 27684541 — intervention group
Group type: COMPARATOR
Intervention: Standard dot-probe protocol (control)
Number of subjects: 113
Study 27684541 — intervention group
Group type: EXPERIMENTAL
Intervention: Both protocols (modified and standard)
Number of subjects: 113
Study 27354766 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized magnesium sulfate (MgSO4)
Number of subjects: 30
Study 27354766 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized salbutamol
Number of subjects: 30
Study 27354766 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized magnesium sulfate (MgSO4) and salbutamol combination
Number of subjects: 30
Study 24381294 — intervention group
Group type: EXPERIMENTAL
Intervention: fMRI decoding of spoken words in one language (e.g., 'horse' in English)
Number of subjects: 0
Study 24381294 — intervention group
Group type: EXPERIMENTAL
Intervention: fMRI response patterns discriminative of spoken words within language
Number of subjects: 0
Study 24381294 — intervention group
Group type: EXPERIMENTAL
Intervention: fMRI response patterns discriminative of spoken words across language
Number of subjects: 0
Study 21706151 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) add-on to riluzole, initial dose of 2 IU s.c. every other day, progressively increased to a maximum of 8 IU.
Number of subjects: 0
Study 21706151 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 21706151 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) add-on to riluzole
Number of subjects: 0
Study 21203523 — intervention group
Group type: EXPERIMENTAL
Intervention: Alum-adjuvanted H5 VLP vaccine (5, 10, or 20 µg)
Number of subjects: 0
Study 21203523 — intervention group
Group type: COMPARATOR
Intervention: Placebo (alum)
Number of subjects: 0
Study 21203523 — intervention group
Group type: EXPERIMENTAL
Intervention: Alum-adjuvanted H5 VLP vaccine (10 or 20 µg)
Number of subjects: 0
Study 21203523 — intervention group
Group type: EXPERIMENTAL
Intervention: Alum-adjuvanted H5 VLP vaccine (all doses)
Number of subjects: 0
Study 17882705 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical dexamethasone eyedrops
Number of subjects: 285
Study 17882705 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac drops
Number of subjects: 285
Study 16392974 — intervention group
Group type: EXPERIMENTAL
Intervention: ST with vouchers
Number of subjects: 142
Study 16392974 — intervention group
Group type: EXPERIMENTAL
Intervention: ST with prizes
Number of subjects: 142
Study 16392974 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (ST)
Number of subjects: 142
Study 16392974 — intervention group
Group type: EXPERIMENTAL
Intervention: ST with vouchers and ST with prizes
Number of subjects: 142
Study 16392974 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 142
Study 16392974 — intervention group
Group type: EXPERIMENTAL
Intervention: Longest duration of abstinence achieved during treatment
Number of subjects: 142
Study 12020141 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifactorial intervention program (11-week duration) including education, environmental modifications, exercise programs, drug regimen reviews, provision of hip protectors, and post-fall conferences.
Number of subjects: 439
Study 12020141 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 439
Study 9861554 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive expectancy outcome condition
Number of subjects: 64
Study 9861554 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative expectancy outcome condition
Number of subjects: 64
Study 9861554 — intervention group
Group type: COMPARATOR
Intervention: Neutral (control) condition
Number of subjects: 64
Study 8570882 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose ofloxacin (OFLX) and erythromycin (EM) therapy daily for 6 months
Number of subjects: 0
Study 8570882 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent treatment of OFLX and EM therapy for 6 months
Number of subjects: 0
Study 8570882 — intervention group
Group type: COMPARATOR
Intervention: Erythromycin (EM) therapy for 6 months
Number of subjects: 0
Study 8570882 — intervention group
Group type: COMPARATOR
Intervention: No treatment (neither OFLX nor EM therapy)
Number of subjects: 0
Study 2195006 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomipramine (N = 16)
Number of subjects: 32
Study 2195006 — intervention group
Group type: COMPARATOR
Intervention: Placebo (N = 16)
Number of subjects: 32
Study 2195006 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomipramine
Number of subjects: 32
Study 386492 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone phosphate
Number of subjects: 52
Study 386492 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 30173058 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) or Acceptance and Commitment Therapy (ACT)
Number of subjects: 34
Study 28178175 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine
Number of subjects: 40
Study 28178175 — intervention group
Group type: COMPARATOR
Intervention: Remifentanil
Number of subjects: 40
Study 25261005 — intervention group
Group type: EXPERIMENTAL
Intervention: Helicopter-based ALS rescue concept with in-water ventilation and chest compressions
Number of subjects: 0
Study 25261005 — intervention group
Group type: COMPARATOR
Intervention: Calm water conditions
Number of subjects: 0
Study 23107590 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐fluorouracil (5‐FU) + folinic acid (FA)
Number of subjects: 1651
Study 23107590 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐fluorouracil (5‐FU)
Number of subjects: 1651
Study 23107590 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐fluorouracil (5‐FU) + interferon‐alfa (IFN‐alfa)
Number of subjects: 1651
Study 23107590 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐fluorouracil (5‐FU) + folinic acid (FA) in stage II RC
Number of subjects: 1651
Study 23107590 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐fluorouracil (5‐FU) + folinic acid (FA) in stage III RC
Number of subjects: 1651
Study 23107590 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung metastases
Number of subjects: 1651
Study 21434340 — intervention group
Group type: EXPERIMENTAL
Intervention: Chaipo Granule (CPG) 3 pouches twice a day for 24 weeks
Number of subjects: 60
Study 21434340 — intervention group
Group type: COMPARATOR
Intervention: Routine treatment (salmeterol and fluticasone propionate, salbutamol + ipratropium bromide)
Number of subjects: 60
Study 19842560 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy (2‐4 U/h)
Number of subjects: 80
Study 19842560 — intervention group
Group type: COMPARATOR
Intervention: Routine therapy (no insulin administration)
Number of subjects: 80
Study 16996827 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantable cardioverter defibrillator (ICD) therapy
Number of subjects: 700
Study 16996827 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (control group)
Number of subjects: 700
Study 14593127 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy (CEA)
Number of subjects: 104
Study 14593127 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular treatment (including percutaneous transluminal angioplasty, balloon-expandable stent, self-expandable stent)
Number of subjects: 104
Study 14593127 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 104
Study 10924782 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined hepatitis A/B vaccine (Twinrix Adult)
Number of subjects: 5
Study 10924782 — intervention group
Group type: COMPARATOR
Intervention: Monovalent vaccines (Havrix 1440+Engerix‐B or Vaqta+Gen H‐B‐Vax)
Number of subjects: 5
Study 8936360 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin
Number of subjects: 7
Study 8936360 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 1583173 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcipotriol (50 micrograms/gm) ointment
Number of subjects: 409
Study 1583173 — intervention group
Group type: COMPARATOR
Intervention: Betamethasone 17-valerate (1 mg/gm) ointment
Number of subjects: 409
Study 2931148 — intervention group
Group type: EXPERIMENTAL
Intervention: fenoterol
Number of subjects: 96
Study 2931148 — intervention group
Group type: EXPERIMENTAL
Intervention: ipratropium bromide
Number of subjects: 96
Study 2931148 — intervention group
Group type: COMPARATOR
Intervention: FEV1
Number of subjects: 96
Study 31474193 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular thrombectomy
Number of subjects: 47
Study 31474193 — intervention group
Group type: COMPARATOR
Intervention: Medical management
Number of subjects: 47
Study 30513818 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide (1.8 mg/day)
Number of subjects: 35
Study 30513818 — intervention group
Group type: COMPARATOR
Intervention: Lifestyle counseling
Number of subjects: 35
Study 30513818 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions (Liraglutide and Lifestyle counseling)
Number of subjects: 35
Study 26656041 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrust spinal manipulation (SM)
Number of subjects: 192
Study 26656041 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonthrust spinal manipulation (SM)
Number of subjects: 192
Study 26656041 — intervention group
Group type: COMPARATOR
Intervention: Wait list control
Number of subjects: 192
Study 25475247 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrative medicine rehabilitation (IMR) group receiving acupuncture and Chinese herbs in addition to basic Western medicine and rehabilitation treatment.
Number of subjects: 360
Study 25475247 — intervention group
Group type: COMPARATOR
Intervention: Conventional rehabilitation (CR) group not receiving acupuncture and Chinese herbal medicine.
Number of subjects: 360
Study 25475247 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrative medicine rehabilitation (IMR) group
Number of subjects: 360
Study 25475247 — intervention group
Group type: COMPARATOR
Intervention: Conventional rehabilitation (CR) group
Number of subjects: 360
Study 25475247 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 360
Study 22116310 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance Exercise Training (RET)
Number of subjects: 30
Study 22116310 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise Training (AET)
Number of subjects: 30
Study 22116310 — intervention group
Group type: COMPARATOR
Intervention: Wait List (WL)
Number of subjects: 30
Study 22116310 — intervention group
Group type: COMPARATOR
Intervention: Combined exercise conditions (RET and AET)
Number of subjects: 30
Study 20823897 — intervention group
Group type: EXPERIMENTAL
Intervention: Folinic acid (5‐formyltetrahydrofolate) at a dosage of 70 μg/kg/day for 2 weeks
Number of subjects: 37
Study 20823897 — intervention group
Group type: COMPARATOR
Intervention: Control group (no folinic acid treatment)
Number of subjects: 37
Study 18257178 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal electroacupuncture (EA) at Daheng (SP 15), Fujie (SP 14), Tianshu (ST 25), Shuidao (ST 28), once a day for 30 minutes.
Number of subjects: 80
Study 18257178 — intervention group
Group type: COMPARATOR
Intervention: Cisapride, 10 mg orally, three times a day.
Number of subjects: 80
Study 15694243 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychotropic drugs
Number of subjects: 124
Study 15694243 — intervention group
Group type: COMPARATOR
Intervention: Control group (no drug exposure)
Number of subjects: 124
Study 15570143 — intervention group
Group type: EXPERIMENTAL
Intervention: Historical Physical Activity Questionnaire (HPAQ) recall
Number of subjects: 163
Study 15570143 — intervention group
Group type: COMPARATOR
Intervention: Original Physical Activity Questionnaires (1982, 1985, 1995, 1999)
Number of subjects: 163
Study 11390725 — intervention group
Group type: EXPERIMENTAL
Intervention: AN‐69 group (n=13)
Number of subjects: 24
Study 11390725 — intervention group
Group type: COMPARATOR
Intervention: CELL group (n=11)
Number of subjects: 24
Study 9223023 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride (10 mg, qid) in REFLUX-group (N = 43)
Number of subjects: 127
Study 9223023 — intervention group
Group type: EXPERIMENTAL
Intervention: Domperidone (20 mg, tid) in REFLUX-group (N = 43)
Number of subjects: 127
Study 9223023 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride (10 mg, qid) in DYSPEPSIA-group (N = 84)
Number of subjects: 127
Study 9223023 — intervention group
Group type: EXPERIMENTAL
Intervention: Domperidone (20 mg, tid) in DYSPEPSIA-group (N = 84)
Number of subjects: 127
Study 9223023 — intervention group
Group type: EXPERIMENTAL
Intervention: Both therapies (Cisapride and Domperidone)
Number of subjects: 127
Study 8354325 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate (SCG) 5 mg, inhaled four times a day for 3 weeks
Number of subjects: 16
Study 8354325 — intervention group
Group type: COMPARATOR
Intervention: Placebo, inhaled four times a day for 3 weeks
Number of subjects: 16
Study 3814542 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 Hz electric currents (500 microamperes)
Number of subjects: 76
Study 3814542 — intervention group
Group type: COMPARATOR
Intervention: Sham exposure
Number of subjects: 76
Study 31495952 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.025 mg/kg teduglutide
Number of subjects: 59
Study 31495952 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05 mg/kg teduglutide
Number of subjects: 59
Study 31495952 — intervention group
Group type: COMPARATOR
Intervention: SOC (standard of care)
Number of subjects: 59
Study 28901811 — intervention group
Group type: EXPERIMENTAL
Intervention: Horizontal adduction stretch
Number of subjects: 63
Study 28901811 — intervention group
Group type: EXPERIMENTAL
Intervention: Supine sleeper stretch
Number of subjects: 63
Study 28901811 — intervention group
Group type: COMPARATOR
Intervention: Control (no stretch)
Number of subjects: 63
Study 27852236 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferric carboxymaltose (FCM) 200 mg
Number of subjects: 42
Study 27852236 — intervention group
Group type: COMPARATOR
Intervention: Iron sucrose (IS)
Number of subjects: 42
Study 27852236 — intervention group
Group type: EXPERIMENTAL
Intervention: Both FCM and IS
Number of subjects: 42
Study 25022782 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticipatory processing task
Number of subjects: 59
Study 25022782 — intervention group
Group type: COMPARATOR
Intervention: Distraction task
Number of subjects: 59
Study 22285177 — intervention group
Group type: EXPERIMENTAL
Intervention: Real acupuncture
Number of subjects: 23
Study 22285177 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 23
Study 20688319 — intervention group
Group type: EXPERIMENTAL
Intervention: Worry
Number of subjects: 61
Study 20688319 — intervention group
Group type: EXPERIMENTAL
Intervention: Imaginal processing
Number of subjects: 61
Study 20688319 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation
Number of subjects: 61
Study 18853555 — intervention group
Group type: EXPERIMENTAL
Intervention: Aligned attractive bottom halves of faces
Number of subjects: 0
Study 18853555 — intervention group
Group type: COMPARATOR
Intervention: Misaligned and upside-down presentations of faces
Number of subjects: 0
Study 16632570 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% carbohydrate/electrolyte drink (CHO‐E)
Number of subjects: 14
Study 16632570 — intervention group
Group type: COMPARATOR
Intervention: Water
Number of subjects: 14
Study 14643741 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct victimization at school by peers
Number of subjects: 998
Study 14643741 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct victimization at home by parents
Number of subjects: 998
Study 14643741 — intervention group
Group type: EXPERIMENTAL
Intervention: Vicarious victimization (exposure to domestic violence)
Number of subjects: 998
Study 14643741 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender and age as predictors
Number of subjects: 998
Study 14643741 — intervention group
Group type: EXPERIMENTAL
Intervention: Relational victimization at school
Number of subjects: 998